

Supplementary table 4: Multivariable analysis of the association between earlobe crease (unilateral or bilateral) and selected cardiovascular risk factors, CoLaus study, Lausanne, 2009-2012.

Adjusting for	Age and gender				Age, gender and body mass index				
	Earlobe crease	Absent (n=3829)	Unilateral (n=373)	Bilateral (n=429)	P-value for trend	Absent (n=3829)	Unilateral (n=373)	Bilateral (n=429)	P-value for trend
BMI (kg/m ²)	26.0 ± 0.1	26.8 ± 0.2	27.2 ± 0.2	<0.001	-	-	-	-	-
Abdominal obesity	1 (ref.)	1.17 (0.93; 1.46)	1.24 (1.00; 1.53)	0.05	1 (ref.)	0.95 (0.67; 1.33)	0.78 (0.57; 1.06)		0.12
Smoking status									
Never	-								
Former	1 (ref.)	0.97 (0.76; 1.24)	1.38 (1.10; 1.75)	NA	1 (ref.)	0.97 (0.76; 1.24)	1.33 (1.05; 1.69)		NA
Current	1 (ref.)	0.91 (0.67; 1.23)	1.33 (1.00; 1.77)	NA	1 (ref.)	0.96 (0.71; 1.30)	1.39 (1.04; 1.86)		NA
Blood pressure status									
SBP (mm Hg) ^a	126 ± 1	126 ± 1	127 ± 1	0.18	126 ± 1	125 ± 1	127 ± 1		0.37
DBP (mm Hg) ^a	78 ± 1	79 ± 1	78 ± 1	0.43	78 ± 1	79 ± 1	78 ± 1		0.89
Hypertension	1 (ref.)	1.41 (1.11; 1.79)	1.40 (1.12; 1.76)	0.003	1 (ref.)	1.34 (1.05; 1.72)	1.26 (1.00; 1.6)		0.054
Lipids (mmol/L) ^b									
Total cholesterol	5.70 ± 0.02	5.69 ± 0.05	5.68 ± 0.05	0.64	5.70 ± 0.02	5.69 ± 0.05	5.66 ± 0.05		0.47
LDL cholesterol	3.45 ± 0.01	3.45 ± 0.05	3.45 ± 0.04	0.89	3.45 ± 0.01	3.43 ± 0.05	3.43 ± 0.04		0.66
HDL cholesterol	1.64 ± 0.01	1.63 ± 0.02	1.59 ± 0.02	0.02	1.64 ± 0.01	1.65 ± 0.02	1.63 ± 0.02		0.78
Triglycerides	1.36 ± 0.01	1.39 ± 0.05	1.41 ± 0.04	0.06 §	1.36 ± 0.01	1.37 ± 0.04	1.35 ± 0.04		0.79 §
Glycaemic status									
Glucose (mmol/L) ^c	5.88 ± 0.02	5.92 ± 0.05	5.98 ± 0.05	0.05	5.88 ± 0.02	5.91 ± 0.05	5.92 ± 0.05		0.64
Insulin (µIU/mL) ^c	8.3 ± 0.1	8.8 ± 0.4	8.8 ± 0.3	0.01 §	8.3 ± 0.1	8.5 ± 0.3	8.3 ± 0.3		0.60 §
HOMA-IR ^c	2.29 ± 0.04	2.38 ± 0.13	2.55 ± 0.12	0.04	2.3 ± 0.04	2.3 ± 0.11	2.37 ± 0.11		0.84

Diabetes	1 (ref.)	1.43 (1.06; 1.93)	1.44 (1.08; 1.91)	0.01	1 (ref.)	1.29 (0.94; 1.77)	1.22 (0.90; 1.65)	0.20
High HOMA-IR	1 (ref.)	1.21 (0.96; 1.53)	1.17 (0.94; 1.47)	0.16	1 (ref.)	1.03 (0.78; 1.35)	0.89 (0.68; 1.15)	0.36
Metabolic syndrome	1 (ref.)	1.31 (1.04; 1.64)	1.26 (1.01; 1.56)	0.04	1 (ref.)	1.15 (0.87; 1.51)	0.94 (0.72; 1.21)	0.62

For quantitative variables, multivariable analyses were performed by ANOVA and the results are expressed as adjusted mean \pm standard error. For categorical variables (excluding smoking), multivariable analyses were performed by logistic regression and results are expressed as odds ratio (95% confidence interval). For smoking, multivariable analyses were performed using multivariate (polytomous) logistic regression and the results are expressed as relative risk ratio (95% confidence interval). § P-value calculated on log-transformed values. ^a, adjusting for antihypertensive medication; ^b, adjusting for hypolipidemic medication; ^c, adjusting for antidiabetes medication.

CVRF, cardiovascular risk factors; **BMI**, body mass index; **SBP**, systolic blood pressure; **DBP**, diastolic blood pressure; **LDL**, low-density lipoprotein; **HDL**, high-density lipoprotein; **HOMA-IR**, homeostatic model assessment of insulin resistance; **high HOMA-IR** is defined as a HOMA-IR ≥ 2.6 ; **abdominal obesity** and **metabolic syndrome** are defined by the NCEP ATP-III criteria; **hypertension** is defined as SBP > 140 or DBP > 90 mm Hg or antihypertensive medication; **diabetes** is defined as fasting plasma glucose > 7.0 mmol/L or anti-diabetes medication; **NA**, not assessable.